The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Key Laboratory of Ophthalmology, Chongqing, China.
Invest Ophthalmol Vis Sci. 2022 Jul 8;63(8):25. doi: 10.1167/iovs.63.8.25.
Retinal microglia promote angiogenesis and vasculopathy in oxygen-induced retinopathy (OIR); however, its specific molecular mechanism in the formation of retinal angiogenesis remains unclear. The lectin galactoside-binding soluble 3 binding protein (LGALS3BP), a member of the scavenger receptor cysteine-rich (SRCR) domain protein family, is involved in tumor neovascularization, and we therefore hypothesized that LGALS3BP plays an active role in microglia-induced angiogenesis.
The expression of LGALS3BP in microglia was detected by immunofluorescence, RT-qPCR, and western blotting. Functional assays of human umbilical vein endothelial cells (HUVECs) such as migration, proliferation, and tube formation were measured by Transwell, EdU, and Matrigel assays. Angiogenesis-related factors and PI3K/AKT levels were detected by western blotting. The relationship between LGALS3BP and PI3K or HIF-1α was investigated by immunoprecipitation.
Our results showed that the expression of LGALS3BP was significantly increased in microglia surrounding neovascularization of the OIR mice and was also upregulated in human microglial clone 3 (HMC3) cells after hypoxia. Moreover, HUVECs co-cultured with hypoxic HMC3 cells showed increased migration, proliferation, and tube formation, as well as levels of angiogenesis-related factor. However, the proangiogenic ability and angiogenesis-related factor expression of HMC3 cells was suppressed after silencing LGALS3BP. LGALS3BP induces the upregulation of angiogenesis-related factors through the PI3K/AKT pathway and then promotes angiogenesis in microglia.
Collectively, our findings suggest that LGALS3BP in microglia plays an important role in angiogenesis, suggesting a potential therapeutic target of LGALS3BP for angiogenesis.
视网膜小胶质细胞促进氧诱导视网膜病变(OIR)中的血管生成和血管病变;然而,其在视网膜血管生成形成中的特定分子机制尚不清楚。凝集素半乳糖结合可溶性 3 结合蛋白(LGALS3BP)是清道夫受体富含半胱氨酸(SRCR)域蛋白家族的成员,参与肿瘤新生血管形成,因此我们假设 LGALS3BP 在小胶质细胞诱导的血管生成中发挥积极作用。
通过免疫荧光、RT-qPCR 和 Western blot 检测 LGALS3BP 在小胶质细胞中的表达。通过 Transwell、EdU 和 Matrigel 测定人脐静脉内皮细胞(HUVEC)的迁移、增殖和管形成等功能。通过 Western blot 检测血管生成相关因子和 PI3K/AKT 水平。通过免疫沉淀研究 LGALS3BP 与 PI3K 或 HIF-1α 的关系。
我们的结果表明,LGALS3BP 的表达在 OIR 小鼠新生血管周围的小胶质细胞中显著增加,并且在缺氧后的人小胶质细胞克隆 3(HMC3)细胞中也上调。此外,与缺氧 HMC3 细胞共培养的 HUVECs 表现出迁移、增殖和管形成增加,以及血管生成相关因子水平增加。然而,沉默 LGALS3BP 后,HMC3 细胞的促血管生成能力和血管生成相关因子表达受到抑制。LGALS3BP 通过 PI3K/AKT 途径诱导血管生成相关因子的上调,从而促进小胶质细胞中的血管生成。
总之,我们的研究结果表明小胶质细胞中的 LGALS3BP 在血管生成中起重要作用,提示 LGALS3BP 可能是血管生成的潜在治疗靶点。